SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-072011
Filing Date
2022-03-10
Accepted
2022-03-10 16:32:56
Documents
12
Period of Report
2022-03-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d306646d8k.htm   iXBRL 8-K 23269
  Complete submission text file 0001193125-22-072011.txt   144315

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fulc-20220304.xsd EX-101.SCH 2864
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20220304_lab.xml EX-101.LAB 17980
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20220304_pre.xml EX-101.PRE 11264
6 EXTRACTED XBRL INSTANCE DOCUMENT d306646d8k_htm.xml XML 3350
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 22729521
SIC: 2834 Pharmaceutical Preparations